Mind Cure Health Begins Research Into Psychedelic Compounds

Mind Cure Health (CSE: MCUR) has reached a milestone, with the company this morning announcing its translational research program that will initially focus on the compounds of psilocybin, ibogaine, and ketamine. Research into the compounds is said to be largely focused on the treatment of physical and psychological pain and related mental health illnesses.

Translational research in layman terms is multidisciplinary and involves applying lab research and preclinical studies to developing clinical trials and studies in humans. Unlike applied science, translation research is said to be solely focused on improving health outcomes.

The program is intended to enable Mind Cure to investigate the compounds of psilocybin, ketamine and ibogaine for use in pharmaceuticals. All three are said to have demonstrated safety profiles that have a proven efficacy, but the compounds have yet to be optimized for medical use. The research will be focused on “delivering validation of commercially viable medicines, methods and tools to address numerous priorities in treating mental health.”

“Despite social stigmas, many classical psychedelics have safely demonstrated profound therapeutic effectiveness with alleviating all forms of pain associated with neurological trauma and chronic diseases. We begin our research with tremendous promise for new medicines that share structural similarities with improved receptor targeting, dosing, and therapeutic profiles.”

Dr. Ryan Hartwell

The company is currently focused on executing on this approach of research into psychedelics as a means of expediting research and development programs. Further, the program is said to holistically account for the lasting effects on quality of life and clinical outcomes in patients as a result of the mixed effects of physical and psychological pain.

Mind Cure Health last traded at $0.65 on the CSE.


FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Gold is Up 30%, But the Real Bull Market is Only Starting Now! | Adrian Day

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

Mind Cure Announces New Product, Launch Dates For Nootropic Products

Mind Cure Health (CSE: MCUR) this morning announced that it intends to bring a new...

Tuesday, December 29, 2020, 07:14:06 AM

Mind Cure Closes Acquisition Deal, To Be Renamed LNG Energy

Mind Cure Health Inc. (CSE: MCUR) has closed the previously announced business combination with LNG...

Wednesday, August 16, 2023, 09:38:44 AM

Mind Cure: Mental Health Focused Firm To Commence Trading Monday

Mind Cure Health (CSE: MCUR) is the latest issue to hit the Canadian Securities Exchange...

Sunday, September 20, 2020, 09:00:00 AM

Mind Cure Set To Launch Products Into Psychedelic Therapy Adaptogen Supplement Category

Mind Cure Health (CSE: MCUR) has completed the development of its first products. The company...

Tuesday, January 26, 2021, 08:43:59 AM

Mind Cure Enters LOI To Acquire Ephiphany360 Digital Therapeutics Platform

Mind Cure Health (CSE: MCUR) is getting into the digital therapeutics space. The company announced...

Wednesday, October 21, 2020, 08:47:34 AM